RT info:eu-repo/semantics/article
T1 Long COVID a new derivative in the chaos of SARS-CoV-2 infection: the emergent pandemic?
A1 Fernández Lázaro, Diego
A1 Sánchez Serrano, Nerea
A1 Mielgo Ayuso, Juan Francisco
A1 García Hernández, Juan Luis
A1 González Bernal, Jerónimo J.
A1 Seco Calvo, Jesús
K1 COVID-19 (Disease)
K1 Symptoms
K1 Terapia
K1 Pandemia
K1 Infección
K1 Enfermedades infecciosas
K1 Long COVID
K1 Pathways
K1 Biomarkers
K1 2420 Virología
AB Coronavirus disease 2019 (COVID-19) is a multisystem illness caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which can manifest with a multitude of symptoms in the setting of end-organ damage, though it is predominantly respiratory. However, various symptoms may remain after acute SARS-CoV-2 infection, and this condition is referred to as “Long COVID” (LC). Patients with LC may develop multi-organ symptom complex that remains 4–12 weeks after the acute phase of illness, with symptoms intermittently persisting over time. The main symptoms are fatigue, post-exertional malaise, cognitive dysfunction, and limitation of functional capacity. Pediatric patients developed the main symptoms of LC like those described in adults, although there may be variable presentations of LC in children. The underlying mechanisms of LC are not clearly known, although they may involve pathophysiological changes generated by virus persistence, immunological alterations secondary to virus–host interaction, tissue damage of inflammatory origin and hyperactivation of coagulation. Risk factors for developing LC would be female sex, more than five early symptoms, early dyspnea, previous psychiatric disorders, and alterations in immunological, inflammatory and coagulation parameters. There is currently no specific treatment for LC, but it could include pharmacological treatments to treat symptoms, supplements to restore nutritional, metabolic, and gut flora balance, and functional treatments for the most disabling symptoms. In summary, this study aims to show the scientific community the current knowledge of LC.
PB MDPI
SN 2077-0383
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/59055
UL https://uvadoc.uva.es/handle/10324/59055
LA eng
NO Journal of Clinical Medicine,2021, Vol. 10, Nº. 24, 5799
NO Producción Científica
DS UVaDOC
RD 21-may-2024